Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of therapeutics and diagnostics aimed at treating and preventing human diseases and alleviating suffering. The company focuses on addressing unmet medical needs across several key therapeutic areas, including central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Headquartered in Berkeley Heights, New Jersey, Tonix is committed to advancing scientific innovation to improve patient care and public health.

Tonix's portfolio encompasses commercial products, as well as numerous development and discovery-stage candidates. Key commercial products include TONMYA (cyclobenzaprine HCl sublingual tablet) for the management of fibromyalgia, and the acute migraine treatments Zembrace SymTouch and Tosymra. The company's robust pipeline features TNX-102 SL for major depressive disorder and Long COVID, TNX-601 ER for major depressive disorder, TNX-801 as a vaccine platform for smallpox, mpox, and COVID-19, TNX-1500 for organ transplant rejection and autoimmune conditions, and TNX-2900 for Prader-Willi Syndrome, among others.

Dr. Seth Lederman serves as the CEO, President, and Chairman of the Board. Recent notable developments include the conditional acceptance of the trade name TONMYA™ for TNX-102 SL in fibromyalgia and its commercial launch in November 2025. Tonix has also secured commercial payer agreements for TONMYA, significantly expanding its coverage. In June 2025, the company was included in the Russell 3000® and 2000® Indexes, enhancing its visibility among institutional investors. While the company demonstrates strong clinical momentum and pipeline progress, it continues to navigate challenges such as ongoing operating losses and cash burn.